JP7606479B2 - エストロゲン関連受容体アルファ（ＥＲＲα）モジュレーター - Google Patents

エストロゲン関連受容体アルファ（ＥＲＲα）モジュレーター Download PDF

Info

Publication number
JP7606479B2
JP7606479B2 JP2021577993A JP2021577993A JP7606479B2 JP 7606479 B2 JP7606479 B2 JP 7606479B2 JP 2021577993 A JP2021577993 A JP 2021577993A JP 2021577993 A JP2021577993 A JP 2021577993A JP 7606479 B2 JP7606479 B2 JP 7606479B2
Authority
JP
Japan
Prior art keywords
pyridin
pyrazolo
trifluoromethyl
methoxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021577993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538363A5 (https=
JP2022538363A (ja
Inventor
ヘーラルト ヘンリクス レンメルス，ヤープ
デレテイ，オイゲン
ペトルス ヘーラルト クロンプ，ヨハネス
マリア へーラルト バーバラ カルス，ジョゼフ
オーブリー，アルトゥール
Original Assignee
リード ファーマ ホールディング ビー．ブイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リード ファーマ ホールディング ビー．ブイ． filed Critical リード ファーマ ホールディング ビー．ブイ．
Publication of JP2022538363A publication Critical patent/JP2022538363A/ja
Publication of JP2022538363A5 publication Critical patent/JP2022538363A5/ja
Application granted granted Critical
Publication of JP7606479B2 publication Critical patent/JP7606479B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2021577993A 2019-07-04 2020-07-01 エストロゲン関連受容体アルファ（ＥＲＲα）モジュレーター Active JP7606479B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19184515.5 2019-07-04
EP19184515 2019-07-04
PCT/EP2020/068574 WO2021001453A1 (en) 2019-07-04 2020-07-01 ESTROGEN-RELATED RECEPTOR ALPHA (ERRα) MODULATORS

Publications (3)

Publication Number Publication Date
JP2022538363A JP2022538363A (ja) 2022-09-01
JP2022538363A5 JP2022538363A5 (https=) 2023-07-07
JP7606479B2 true JP7606479B2 (ja) 2024-12-25

Family

ID=67180693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021577993A Active JP7606479B2 (ja) 2019-07-04 2020-07-01 エストロゲン関連受容体アルファ（ＥＲＲα）モジュレーター

Country Status (17)

Country Link
US (1) US12527774B2 (https=)
EP (1) EP3994138B1 (https=)
JP (1) JP7606479B2 (https=)
KR (1) KR20220029719A (https=)
CN (1) CN114341135B (https=)
AR (1) AR119348A1 (https=)
AU (1) AU2020298779A1 (https=)
BR (1) BR112021026687A2 (https=)
CO (1) CO2021017619A2 (https=)
ES (1) ES3032908T3 (https=)
IL (1) IL289510B2 (https=)
MA (1) MA56444A (https=)
MX (1) MX2022000165A (https=)
PH (1) PH12021553204A1 (https=)
UA (1) UA129204C2 (https=)
WO (1) WO2021001453A1 (https=)
ZA (1) ZA202200591B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023011456A1 (en) * 2021-08-03 2023-02-09 Beigene, Ltd. Pyrazolopyridinone compounds
EP4486741A4 (en) 2022-03-01 2026-04-08 Insilico Medicine Ip Ltd Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses
WO2023165525A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103288823A (zh) 2012-02-23 2013-09-11 华东理工大学 N,n’-芳基取代脲类化合物及其用途
US20190161490A1 (en) 2016-06-27 2019-05-30 Sung Yeoun HWANG Novel aryl ethene derivative and pharmaceutical composition containing same as active ingredient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016887B1 (ru) * 2007-03-07 2012-08-30 Янссен Фармацевтика Н.В. ЗАМЕЩЁННЫЕ ФЕНОКСИАМИНОТИАЗОЛОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ РОДСТВЕННОГО ЭСТРОГЕНОВОМУ РЕЦЕПТОРУ РЕЦЕПТОРА-α
NZ579372A (en) 2007-03-07 2012-02-24 Janssen Pharmaceutica Nv Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators
CN104119285B (zh) 2013-04-28 2016-06-29 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103288823A (zh) 2012-02-23 2013-09-11 华东理工大学 N,n’-芳基取代脲类化合物及其用途
US20190161490A1 (en) 2016-06-27 2019-05-30 Sung Yeoun HWANG Novel aryl ethene derivative and pharmaceutical composition containing same as active ingredient

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. A. Dudinov et al.，Three-component condensation of 2,4-diaminothiazoles with aldehydes and Meldrum’s acid. The synthesis of 7-aryl- and 7-alkyl-6,7-dihydro-4H-thiazolo[4,5-b]pyridin-5-ones，Russian Chemical Bulletin International,，2008年，57(8)，1740-1743
Frimurer, Thomas M. et al.，Model-Based Discovery of Synthetic Agonists for the Zn2+-Sensing G-Protein-Coupled Receptor 39 (GPR39) Reveals Novel Biological Functions，Journal of Medicinal Chemistry ，2017年，60(3)，886-898

Also Published As

Publication number Publication date
IL289510A (en) 2022-03-01
ES3032908T3 (en) 2025-07-28
MA56444A (fr) 2022-05-11
AR119348A1 (es) 2021-12-09
JP2022538363A (ja) 2022-09-01
IL289510B2 (en) 2025-08-01
PH12021553204A1 (en) 2022-11-07
US20220387401A1 (en) 2022-12-08
CN114341135B (zh) 2025-03-18
EP3994138B1 (en) 2025-04-02
US20250268872A2 (en) 2025-08-28
UA129204C2 (uk) 2025-02-05
US12527774B2 (en) 2026-01-20
CO2021017619A2 (es) 2022-04-19
KR20220029719A (ko) 2022-03-08
IL289510B1 (en) 2025-04-01
MX2022000165A (es) 2022-05-20
ZA202200591B (en) 2023-07-26
EP3994138C0 (en) 2025-04-02
AU2020298779A1 (en) 2022-02-17
CN114341135A (zh) 2022-04-12
BR112021026687A2 (pt) 2022-03-08
CA3144891A1 (en) 2021-01-07
EP3994138A1 (en) 2022-05-11
WO2021001453A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
JP7723011B2 (ja) イミダゾール３－オキシド誘導体系ａｃｓｓ２阻害剤及びその使用方法
BR112013026137B1 (pt) pirimidinil-pirróis substituídos ativos como inibidores da quinase
US20110201815A1 (en) Fused heterocyclic derivative and use thereof for medical purposes
JP7606479B2 (ja) エストロゲン関連受容体アルファ（ＥＲＲα）モジュレーター
CN111601790A (zh) 作为蛋白激酶抑制剂的杂芳基化合物
JP7302794B2 (ja) Ｔｎｉｋを阻害するための化合物及びその医学的使用
US20240124469A1 (en) Pim kinase inhibitor
RU2512547C2 (ru) Содержащее конденсированную кольцевую структуру производное и его применение в медицине
CN111526877A (zh) 用于ire1抑制的化合物和组合物
JP7629912B2 (ja) エストロゲン関連受容体アルファ（ＥＲＲα）モジュレーター
KR20210022646A (ko) 시아노트리아졸 화합물 및 이의 용도
CN110407839B (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
CA3144891C (en) Estrogen-related receptor alpha (err.alpha.) modulators
EA046701B1 (ru) МОДУЛЯТОРЫ ЭСТРОГЕНСВЯЗАННЫХ РЕЦЕПТОРОВ АЛЬФА (ERRα)
HK40069843A (en) Estrogen-related receptor alpha (erralpha) modulators
HK40069843B (en) Estrogen-related receptor alpha (erralpha) modulators
EP4488276A1 (en) Novel heterocyclic compound and pharmaceutical composition comprising same
US20260124197A1 (en) Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising same
EA047211B1 (ru) МОДУЛЯТОРЫ СВЯЗАННОГО С ЭСТРОГЕНОМ РЕЦЕПТОРА АЛЬФА (ERRα)
HK40073444A (en) Estrogen-related receptor alpha (err-alpha) modulators
HK40073444B (en) Estrogen-related receptor alpha (err-alpha) modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230629

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241213

R150 Certificate of patent or registration of utility model

Ref document number: 7606479

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150